focus -WSS

focus

author：Wikipedia 2025-09-30 00:35:48 - browse：5977

Steven Pearson — ICER President Steven D. Pearson Craig F. Walker/The Boston Globe

Meetings of the Institute for Clinical and Economic Review don’t usually get one’s heart pumping. But a meeting Thursday at the Massachusetts Institute of Technology may prove to be the exception to that rule.

Patients Rising Now, an advocacy group that says it promotes transparency in health care and that is a fierce opponent of ICER’s, is expected to face off with the self-professed “watchdog of drug pricing” as it reviews three drugs for Duchenne muscular dystrophy.

Dozens of Duchenne patients and their families — many of whom also express concern that ICER’s review could undermine insurers’ already tepid interest in the treatments — are also expected to be in attendance.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： A rare thyroid diagnosis led to unexpected, all

leisure time

WSS

Medicaid rebukes states for mistakenly disenrolling children

Weighted lottery helped low

Lack of health data on LGBTQ+ people has serious consequences

Harvard's David Sinclair gets blowback over aging

Families look for replacement for GSK asthma drug Flovent

AstraZeneca chief proposes a novel edit to the drug pricing bill

focus

focus

focus

What does generative AI mean for health care? We asked experts

What American doctors can learn from their Israeli counterparts

As demand for Covid shots wanes, Moderna seeks its next success

Ethical issues complicate the benefits of medical crowdfunding

The high cost of giving birth even with insurance

Microsoft's Peter Lee: Generative AI could help doctors be more human

Sports medicine is finally prioritizing gender equality

Biden's 'march

Apple is now the first public company to be valued at $3 trillion

Illumina names Agilent executive as new CEO

hotspot

Florida health officials providing scant details on measles cases

Why Talkspace is targeting Medicare, a tricky market

ALS advocates say criticism of new drugs misses bigger picture

What drug price negotiations mean for Medicare Part D

Change Healthcare: What is it, why does its cyberattack matter?

Humana sues Biden admin over Medicare Advantage audit rule

entertainment

leisure time

knowledge

hotspot